Laboratory tests were performed to measure serum creatinine, hemoglobin, platelet count, P505-15 mw rheumatoid factor, cryoglobulin, IgG, IgA, IgM, 50 % hemolytic complement (CH50) (normal range 32–47 U/mL), C3 (normal range 65–135 mg/dL), and C4 (normal range 13–35 mg/dL). Urine tests included assessment of 24-h protein excretion and assessment of hematuria

[red blood cells per high-power field (RBC/HPF) in resuspended sediment—grade 1 (<1), grade 2 [1–5], grade 3 [6–10], grade 4 MG 132 (11–30), and grade 5 (>30)]. Serum HCV antibody was evaluated by an enzyme-linked immunosorbent assay (ELISA; Abbott Diagnostics, Maidenhead, UK). Anti-HBV antibody was detected with a commercially available ELISA kit. Detection of cryoglobulins Each venous blood sample was promptly injected into a preheated

glass test tube and maintained at 37 °C until the cells and serum were separated in the laboratory. The serum was then allowed to stand at 4 °C for at least 72 h in a hematocrit tube. If agglutination or gelation was detected and dissolution occurred on heating, the presence of cryoglobulins was confirmed. The precipitate/serum volume ratio was measured as the cryocrit [11]. The composition of the cryoprecipitate was characterized by immunofixation electrophoresis. Statistical analysis Statistical analysis was performed using the chi-squared test. Quantitative values were expressed as the mean ± SD, and differences were compared by Wilcoxon’s rank sum test. Elafibranor A probability value <0.05 was considered to indicate statistical significance. The SPSS software package (SPSS 11.0 for windows; SPSS Inc., Chicago, IL, USA) was used for all analyses. Results Comparison Chlormezanone of the cryo-positive and

cryo-negative groups The 35 patients were divided into two groups based on positivity for cryo. Nine patients (25.7 %) were positive for MC and 26 patients (74.3 %) were negative for MC (Table 1). Table 1 Comparison of the cryo-positive and cryo-negative groups   Cryo-positive group Cryo-negative group P value Number 9 26   Age (years) 54.5 ± 11.3 (27–69) 37.5 ± 20.7 (8–84) <0.01 Sex Male 4 Female 5 Male 16 Female 10 ns Primary disease Idio (n = 2) HCV (n = 7) Idio (n = 23) HCV (n = 3) <0.01 Observation period (years) 6 ± 4.1 (3–17) 8 ± 5.9 (3–22) ns Serum creatinine (mg/dL) 1.0 ± 0.6 (0.5–2.7) 1.3 ± 0.9 (0.4–5.2) ns Platelet (×103/μL) 145.8 ± 66.4 (60–275) 227.6 ± 69.2 (41–405) <0.001 Serum IgG (mg/dL) 1748.5 ± 1111.2 (552–4628) 960.1 ± 459.8 (117–2139) <0.01 Serum IgM (mg/dL) 253.3 ± 145.7 (98–682) 148.7 ± 82.6 (44.6–380) <0.01 Serum IgA (mg/dL) 264.5 ± 98.4 (110–513) 255.1 ± 147.8 (53.3–718) ns CH50 (U/mL) 19.1 ± 14.5 (1–42.0) 34.7 ± 13.1 (9–57) <0.001 CH50 (% of patients with a decreased level <31) n = 7 (77.8 %) n = 10 (38.5 %) <0.01 C3 (mg/dL) 56.7 ± 36.2 (2–130) 63.3 ± 27.6 (6.2–126) ns C3 (% of patients with a decreased level <65) n = 6 (66.7 %) n = 15 (57.7 %) ns C4 (mg/dL) 13.6 ± 8.54 (3.9–33.